Latest news with #SherylKingsberg
Associated Press
21-05-2025
- Health
- Associated Press
Consumers Find LivRing® Effectively Addresses Needs for Vaginal Dryness Relief
'I was particularly encouraged by the positive correlation between the reported increases in excitement and desire for intimacy connected to the use of the LivRing.'— Dr. Sheryl A. Kingsberg SALT LAKE CITY, UT, UNITED STATES, May 21, 2025 / / -- J3 Bioscience, a commercialization-stage women's health company, today announced consumer feedback results from LivRing® users that underscore the product's robust performance in providing long-lasting moisturization and lubrication. The findings demonstrate the effectiveness of LivRing in addressing symptoms commonly associated with vaginal dryness - the second most common symptom of menopause - offering a meaningful new option to women seeking clinically tested, non-hormonal, and readily accessible solutions. Summary of Feedback: In a recent consumer feedback review, participants evaluated their experience using a standardized 5-point Likert scale where a rating of (5) corresponded to 'Very Satisfied,' indicating a high level of satisfaction with positive statements regarding the attributes of LivRing, while a rating of (1) represented 'Very Unsatisfied' reflecting minimal or no perceived benefit. The consumer feedback data revealed consistently high levels of satisfaction across all key areas of measurement including: - Perception and First Impressions: Participants reported favorable initial responses, indicating that the product met or exceeded expectations in terms of appearance and physical dimensions. - Daily Use and Comfort: When asked whether they could feel LivRing during daily use, participants gave LivRing an average score approaching 5, and 91% of participants either never or almost never noticed it. - Confidence and Sexual Excitement: Participants reported that their confidence and excitement around sexual activity were positively impacted. - Overall Satisfaction and Advocacy: The overall experience score, along with participants' intent to continue using LivRing, and the likelihood to recommend LivRing all scored very high. J3 Bioscience Board member and Chief of Behavioral Medicine at University Hospitals Cleveland Medical Center, Dr. Sheryl A. Kingsberg added, 'I'm very encouraged by these data as they underpin some important benefits to women that are looking for a non-prescription product. Conditions like vaginal dryness can often have a negative impact on sexual arousal as well as a desire for intimacy. As a researcher in the field of sexual health and medicine, I was particularly encouraged by the positive correlation between the reported increases in excitement and desire for intimacy connected to the use of the LivRing.' 'These results validate our scientific approach to addressing unmet needs in women's health,' said John Fair, President and CEO of J3 Bioscience. 'LivRing is an FDA-cleared, fast-acting, long-lasting, hormone-free product designed to treat the symptoms commonly associated with vaginal dryness, and sets a new standard in the category. We are excited to offer a new treatment option to the millions of women seeking relief from this life-altering condition.' LivRing was designed to offer relief for women experiencing vaginal dryness, which presents with intimacy-related issues, such as lack of lubrication and moisturization, as well as non-intimacy concerns, including persistent and uncomfortable itch or irritation. LivRing is the first and only FDA-cleared, over-the-counter vaginal ring designed to provide a continuous benefit of up to 7-days for each ring, which is the longest in the category. About J3 Bioscience, Inc.: J3 Bioscience, Inc. is a commercialization-stage, specialty women's health and wellness company headquartered in Salt Lake City, Utah. Focused on conditions that impact women throughout the course of their lives, J3 Bioscience develops innovative solutions that address long-overlooked needs in women's health. With a strong commitment to clinical integrity, user-centered design, and long-term impact, J3 Bioscience is advancing a new standard of care in women's health. About LivRing: LivRing®, is the first and only intravaginal ring that is FDA-cleared as a vaginal lubricant and vaginal moisturizer. LivRing is available without a prescription and represents a new and effective solution for women experiencing vaginal dryness. For more information, please visit Media Contact: Madelyn De Los Santos Putnam Insights LLC [email protected] Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
27-02-2025
- Health
- Yahoo
Materna Medical Announces Promising Early Findings from Online Study of Women Experiencing Vaginal Muscle Tightness and Painful Intercourse
Baseline Data Reveals Compelling Characteristics of this Understudied Patient Population MOUNTAIN VIEW, Calif., February 27, 2025--(BUSINESS WIRE)--Materna Medical, Inc., a leading innovator in women's pelvic health solutions, today announced the presentation of baseline data from the ongoing observational clinical trial Prospective On Market Patient-reported Outcomes for Milli™ Vaginal Dilator (the POMPOM study) at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Clinical Meeting in Atlanta, Georgia, from February 27 to March 2, 2025. The abstract, titled "Online Observational Clinical Trial for Assessing the Effectiveness of an FDA-Cleared Expanding Dilator #188," is presented as an e-poster by POMPOM Principal Investigator, Sheryl Kingsberg, Ph.D., Professor, Departments of Reproductive Biology, Psychiatry, and Urology, Case Western Reserve University School of Medicine. This groundbreaking clinical investigation is gathering valuable data on the effectiveness of the Milli Vaginal Dilator to help relieve the symptoms of vaginal muscle tightness and painful intercourse. Milli is a modern, all-in-one expanding dilator with optional vibration. Participants were invited to join POMPOM after self-determining the relevant medical conditions1 and enrolled using a remote online data collection process. The virtual, secure, and confidential format allows convenient and discreet participation, making research accessible to a broad population. Using the POMPOM study's remote platform, 74 qualified subjects enrolled after self-diagnosing their vaginismus and purchasing the Milli Expanding Vaginal Dilator online.1 Initial findings reveal: Over two-thirds (70.3%) of the participants had reported symptoms associated with vaginal muscle tightness for over 3 years (23.0% for 3-5 years) and 47.3% for over 5 years. In addition to the duration of their symptoms, 45.9% of subjects had seen at least 2 healthcare providers for evaluation and treatment. Over a quarter (28.4%) of participants reported severe symptoms, including a visceral reaction – extreme nervousness, palpitations, tremors, hyperventilation, sweating, and shaking – during penetration for a standard pelvic exam. The majority (62.2%) had not given birth to children (nulliparous). While most were new to dilator therapy, 43.3% reported a history of static dilator use. "Study participants enrolled quickly, and their full participation has exceeded our expectations. These early findings confirm the significant unmet need and highlight the potential of online platforms to overcome barriers to care," said Dr. Kingsberg. "By providing convenient and discreet access to information, support, and treatment options, we can empower women to take control of their sexual health and well-being." Millions of People Are Affected Vaginal muscle tightness (vaginismus) is a common yet underreported condition that affects 5-17% of people assigned female at birth at any time in their life.2 The condition is characterized by involuntary muscle contractions of the vaginal wall, making sexual penetration painful, challenging, and impossible. Those afflicted often do not realize this is a treatable medical condition, that help is available, and they are not alone. Materna's Solution The all-in-one Milli Expanding Vaginal Dilator with vibration addresses this condition to support patients suffering from vaginal muscle tightness and related painful sex. In 2019, the Milli device was launched as a wellness trainer and, in 2023, received FDA clearance* to sell over the counter, enabling streamlined access to people suffering from vaginal muscle tightness (vaginismus) and painful intercourse (dyspareunia). "It's interesting to note that 43% of the self-selected subjects have experience using traditional static dilators, either currently or used in the past. This suggests that patients are seeking more modern, innovative treatment options for their pelvic health conditions," said Tracy MacNeal, CEO of Materna Medical. "The POMPOM study is generating data to support the effectiveness of the all- in-one Milli Expanding Vaginal Dilator with vibration, a discrete, convenient, at-home solution for managing this common condition. We are committed to developing innovative solutions that improve women's lives affected by pelvic health conditions." The POMPOM study builds on the initial Milli Vaginal Dilator data previously published in the April 2021 issue of Sexual Medicine Reviews, Vaginal Dilators: Issues and Answers.3 For more information, visit About Materna Medical Materna Medical is a novel OBGYN platform company defining a $25B market with core technologies addressing unmet needs in women's pelvic health. With headquarters in Mountain View, California, Materna pulls from the top minds in MedTech to truly transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical's mission is to empower women to protect their pelvic health. Materna's second product, Materna Prep, is an investigational device used during labor and is intended to reduce pelvic floor muscle injury during vaginal delivery. This product is being studied in the EASE trial, a large, randomized controlled trial running in 20 top US hospitals. Materna aims to transform the standard of care in labor and delivery by protecting pelvic floor health for moms. *Indication Statement: The Milli Vaginal Dilator is a tool intended for controlled dilation of the vagina. It can be used for dilation for an examination, in preparation for a surgical procedure, or to help relieve the symptoms of vaginismus (condition that involves tightening of the vaginal muscles) and related painful sex. 1Tucker S, Javaid S, Rubin R. Accuracy of online patient self-diagnosis of vaginismus/genito-pelvic pain/penetration. Presented at: 25th Annual Fall Scientific Meeting of SMSNA. Scottsdale, Arizona. October 17-20, 2024. 2Melnik, T., Hawton, K., & McGuire, H. (2012). Interventions for vaginismus. Cochrane Database of Systematic Reviews, 2012(12), CD001760. 3Liu M, Juravic M, Mazza G, Krychman ML. Vaginal Dilators: Issues and Answers. Sex Med Rev. 2021 Apr;9(2):212-220. doi: 10.1016/ Epub 2020 Jan 31. PMID: 32014450. View source version on Contacts Media Contact: Debbie DonovanHead of Commercial OperationsMaterna Medical,
